Cancer-Focused Biotech Co. Leads 2 IPOs Netting $561M Total
A cancer-focused biotechnology company and a specialty insurer debuted to receptive public markets on Thursday after pricing initial public offerings that raised $561 million combined under guidance from four law firms,...To view the full article, register now.
Already a subscriber? Click here to view full article